Biocardia Stock Investor Sentiment

BCDA Stock  USD 2.26  0.13  6.10%   
About 74 percent of all Biocardia's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Biocardia suggests that a large number of traders are confidant. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
  

Biocardia Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biocardia can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
few days ago at investing.com         
Biocardia CEO Peter Altman acquires 2,524 in common stock
Investing News at Macroaxis
six days ago at news.google.com         
BioCardia Third Quarter 2024 Earnings US0.61 loss per share - Yahoo Finance
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
BioCardia Receives Buy Rating from HC Wainwright
news
over a week ago at insidermonkey.com         
BioCardia, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at thelincolnianonline.com         
Acquisition by Peter Altman of 1350 shares of Biocardia at 1.87 subject to Rule 16b-3
news
over a week ago at gurufocus.com         
BioCardia Inc Q3 2024 Earnings Call Highlights Breakthroughs and Challenges in Cardiac ...
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
Yahoo News
over a week ago at zacks.com         
Femasys Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over a week ago at www.macroaxis.com         
Acquisition by Allen Jim L. of 12434 shares of Biocardia at 4.43 subject to Rule 16b-3
Macroaxis News
over two weeks ago at zacks.com         
Urogen Pharma Reports Q3 Loss, Tops Revenue Estimates
zacks News
over two weeks ago at zacks.com         
Precision BioSciences Reports Q3 Loss, Misses Revenue Estimates
zacks News
over three weeks ago at zacks.com         
ChromaDex Beats Q3 Earnings and Revenue Estimates
zacks News
over three weeks ago at globenewswire.com         
BioCardia Completes Phase III Randomized Double-Blind Controlled Trialof Autologous Cell Therapy for...
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Arcadia Strengthens Healthcare Data Platform with Faster, Cost-Effective Interoperability Solutions
Yahoo News
over a month ago at finance.yahoo.com         
Disposition of 15808 shares by Edward Gillis of Biocardia at 2.65 subject to Rule 16b-3
Yahoo News
Far too much social signal, news, headlines, and media speculation about Biocardia that are available to investors today. That information is available publicly through Biocardia media outlets and privately through word of mouth or via Biocardia internal channels. However, regardless of the origin, that massive amount of Biocardia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biocardia news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biocardia relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biocardia's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biocardia alpha.

Biocardia Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Allen Jim L. of 50000 shares of Biocardia at 3.0 subject to Rule 16b-3
09/03/2024
2
Acquisition by Peter Altman of 1000 shares of Biocardia at 2.4877 subject to Rule 16b-3
09/13/2024
3
Acquisition by Allen Jim L. of 829 shares of Biocardia at 2.65 subject to Rule 16b-3
10/11/2024
4
Short Interest in BioCardia, Inc. Decreases By 12.6
10/15/2024
5
BioCardia Completes Phase III Randomized Double-Blind Controlled Trialof Autologous Cell Therapy for Ischemic Heart Failure
10/28/2024
6
Urogen Pharma Reports Q3 Loss, Tops Revenue Estimates
11/06/2024
7
Acquisition by Allen Jim L. of 12434 shares of Biocardia at 4.43 subject to Rule 16b-3
11/11/2024
8
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
11/13/2024
9
BioCardia, Inc. Q3 2024 Earnings Call Transcript
11/15/2024
10
Biocardia CEO Peter Altman acquires 2,524 in common stock
11/19/2024

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.